Clinical Trial Update: Daratumumab for Late Antibody-Mediated Rejection [NA]

View source ↗

Summary

A clinical trial is evaluating daratumumab for late antibody-mediated rejection in kidney transplant recipients, and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplant Rejection

Drugs mentioned

• Daratumumab (daratumumab)

Snippet

Sponsor: University Hospital, Martin | Conditions: Kidney Tansplant, Acute Rejection (AR) of Transplanted Kidney | NA | Status: RECRUITING